For U.S. healthcare leaders, trusted data is more important than ever, as their organizations migrate from the fee-for-service model to value-based care. During this transition, healthcare organizations must weigh investments, risks, and trade-offs objectively with quantitative, trustworthy data.
The biopharmaceutical industry has grown impressively in recent years, with its global compound growth rate (CAGR) estimated to reach 8.5% between 2018-2023, outstripping traditional New Chemical Entity sectors.
Oracle’s Clinical One Platform will enable pharmaceutical companies to manage every trial function from randomizing patient participants and collecting and analyzing data to tracking budgets and ensuring trial safety from a single user interface.
The dates are confirmed, the syllabus completed and the course directors are ready to welcome you to the only MBA carefully developed for pharmaceutical leaders: the MBA Pharmaceutical Management.
This whitepaper covers the latest pharmaceutical logistics regulatory developments around the globe such as FMD, MHRA, ICH Q12, PACMP, GMP, DSCSA and more!.
McKesson, Fisher BioServices, GE Healthcare and Cryoport are proud to announce our first annual workshop. Our FREE two-day workshop will provide a forum for industry experts to present and discuss current technological advancements in cryogenic management, regulatory requirements and best practices for processes in the support of regenerative medicine commercialization.
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution. The importance of successfully executing a digital health strategy, as well as creating new financial models and partnerships, cannot be understated.
Overcome the challenges associated with traditional affinity purification methods using Thermo Scientific™ MSIA™ (Mass Spectrometric Immunoassay) microcolumns. Designed for analytical affinity purification, ready-to-use MSIA microcolumns are coated with target-specific affinity ligand to capture low abundant target analytes from even the most complex biological samples.
Recipharm is frequently asked to help its clients select and develop an appropriate dosage form for their inhalation product development programs.When choosing between metered dose inhaler (MDI), dry powder inhaler (DPI) and nebulised dosage forms, a wide range of technical, business and regulatory factors are worthy of evaluation. A few of those key considerations are discussed below